After you've had surgery or experienced a serious physical injury, you are more than likely going to be in a lot of pain. No matter what your pain tolerance is, recovering from surgery or any ...

The media goes wild. This time around, the media is making a fuss about Vertex Pharmaceuticals Incorporated’s suzetrigine, a newly FDA-approved painkiller that also goes by the equally ...

Vertex Pharmaceuticals Incorporated VRTX stock has plunged 25.3% this year so far against the industry’s 5.4% increase. VRTX ...

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbosacral radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...

The drug is suzetrigine under the brand name Journavx. It is now FDA-approved to treat moderate to severe acute pain, which is usually caused by injury, trauma or surgery. Pain is registered in ...

Vertex’s new drug Journavx (suzetrigine) has been hailed as a scientific breakthrough because it allays pain without entering the brain, minimizing the risk of addiction and dependence that can ...

The drug, suzetrigine, is a 50-milligram prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx. “A new non-opioid analgesic ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 ...

Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine, becoming the first new class of pain medicine in the US in more than 20 years. The oral NaV1.8 inhibitor has been ...

In a phase 2 study, the company's medication suzetrigine barely performed better than a placebo in treating painful lumbosacral radiculopathy (LSR), a condition that causes pain in patients' lower ...